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ABSTRACT
Cancer stem cells (CSCs) retain the capacity to propagate themselves through 
self-renewal and to produce heterogeneous lineages of cancer cells constituting the 
tumor. Novel drugs that target CSCs can potentially eliminate the tumor initiating cell 
population therefore resulting in complete cure of the cancer. We recently established 
a CSC-like model using induced pluripotent stem cell (iPSC) technology to reprogram 
and partially differentiate human mammary epithelial MCF-10A cells. Using the 
induced CSC-like (iCSCL) model, we developed a phenotypic drug assay system to 
identify agents that inhibit the stemness and self-renewal properties of CSCs. The 
selectivity of the agents was assessed using three distinct assays characterized by 
cell viability, cellular stemness and tumor sphere formation. Using this approach, 
we found that withaferin A (WA), an Ayurvedic medicine constituent, was a potent 
inhibitor of CSC stemness leading to cellular senescence primarily via the induction of 
p21Cip1 expression. Moreover, WA exhibited strong anti-tumorigenic activity against 
the iCSCL. These results indicate that our iCSCL model provides an innovative high 
throughput platform for a simple, easy, and cost-effective method to search for novel 
CSC-targeting drugs. Furthermore, our current study identified WA as a putative drug 
candidate for abrogating the stemness and tumor initiating ability of CSCs. 
INTRODUCTION
Cancer stem cells (CSCs) are defined as transformed 
stem  cells  that  possess  characteristics  associated  with 
normal stem cells, specifically the ability to self-renew 
and to form hierarchical cancer tissues [1]. Accumulating 
evidence has shown that CSCs reside in various solid 
tumors where they function as a sub-population that plays 
a critical role in tumor initiation, progression, metastasis, 
and recurrence [2, 3]. Therefore, CSCs are considered 
to be a source of the tumor initiation and dissemination 
as well as the acquisition of malignant properties [4]. 
CSCs are commonly resistant to conventional anti-cancer 
treatments such as chemotherapeutic agents and radiation 
therapy resulting in treatment failure [5, 6]. In order to 
overcome  this  treatment  limitation,  novel  therapeutic 
strategies should aim to eliminate CSCs which should 
effectively eradicate the cancer initiating cell population 
within tumor tissues [7]. 
The  development  of  new  treatment  strategies 
that  target  CSCs  is  one  of  the  main  goals  of  anti-
cancer therapy. However, in general, a large-scale drug 
screening process requires a large supply of stable and 
homogeneous cells to ensure reproducibility of the assay 
[8]. It is necessary to separate a sufficient number of 
CSCs from tumor tissue, to amplify the CSCs while stably Oncotarget 8666 www.impactjournals.com/oncotarget
maintaining them in an undifferentiated state in vitro. To 
date, the optimal cell culture conditions for amplifying 
pure CSC populations remain undefined. In fact, in vitro 
amplified  CSCs  are  largely  incompatible  with  the  in 
vivo tumor microenvironment resulting in cell death or 
dormancy [9]. Moreover, cellular heterogeneity of bulk of 
CSC populations may reduce the fidelity and feasibility 
of drug screening assays [10]. Recently, several research 
groups attempted to establish new human CSC models 
[11, 12]. Currently, separation and purification of cancer 
stem-like cells from some cancer cell lines is the most 
common and easy method. Cancer stem-like cells can 
be enriched by collecting cells expressing CSC markers 
such as CD133 and CD44 [13, 14]. ALDEFLUOR™ is 
a non-immunological method that identifies human stem/
progenitor cells based on their aldehyde dehydrogenase 
(ALDH)  activity  [15].  Interestingly,  co-expression  of 
CD133+ and CD44+ with high ALDH activity identified 
an  enriched  CSC-like  population  within  established 
cancer cell lines [16]. An alternative approach for the 
enrichment of CSCs is the use of transformed cancer 
cell lines that were forced to undergo the tumor sphere 
formation  or  the  epithelial-to-mesenchymal  transition 
(EMT) [17, 18]. These cells expressed surrogate CSC 
markers and displayed putative tumorigenic properties 
in vivo, which highlights the potential suitability of this 
model for the discovery of compounds that can selectively 
target CSCs [19]. Despite the advances in modeling CSCs, 
the genetic variability with chromosomal instabilities in 
over-passaged cell lines remains a limitation that prevents 
consistent findings in large-scale drug screening assay. 
Furthermore, tumor sphere culture cannot always enrich 
cancer stem-like cells from cancer cell lines [20]. 
To  overcome  the  aforementioned  caveats,  we 
recently developed a novel method of inducing cancer 
stem-like cells through the reprogramming and partial 
differentiation  of  the  immortalized  human  mammary 
epithelial MCF-10A cell line which has a low genetic 
mutation rate [21]. These cells, termed induced cancer 
stem cell-like 10A (iCSCL-10A), express cancer stem 
markers (CD44, CD133 and ALDH1) and show much 
higher sphere forming ability than conventional cancer 
cell lines even in regular cell culture media supplemented 
with fetal bovine serum [22]. Furthermore, only several 
hundreds of iCSCL-10A cells can form hierarchically-
organized tumors in immunosuppressed mice in a short 
period [22]. In our current study, we utilized iCSCL-10A 
cells to identify agents that selectively prohibit the traits 
of CSCs. Rather than simply identifying drugs that kill 
CSCs, we sought to identify compounds that interfere with 
the self-renewal and pluripotent properties of CSCs [23]. 
We found that Withaferin A (WA) was a putative anti-CSC 
drug candidate that altered the tumorigenic properties of 
CSC via the induction of cellular senescence. Our current 
approach can thus provide an useful option for future 
development of anti-CSC drugs.
RESULTS
Development of a drug screening assay system 
based on CSC properties
We recently established a new CSC-like model, 
iCSCL-10A  cells,  via  the  introduction  of  defined 
reprogramming  factors  and  subsequent  partial  cell 
differentiation  from  MCF-10A  cells  [22,  24].  These 
proliferating CSC-like cells express characteristic CSC 
markers,  display  a  malignant  phenotype  in vitro and 
form tumors of multiple lineages following injection into 
immunocompromised mice (Figure 1A) [25]. We utilized 
iCSCL-10A cells for our high-throughput drug screening 
assay to monitor phenotypic traits of CSCs in the presence 
of various compounds. We aimed to identify compounds 
that selectively target CSCs by monitoring the specific 
properties of CSC, such as self-renewal and stemness, 
without prominent cell toxicity. The activity/selectivity of 
the agents was assessed using three distinct assays: 1) cell 
viability assay for cell toxicity, 2) alkaline phosphatase 
(ALP) assay for cellular stemness, and 3) tumor sphere 
forming assay for self-renewal. The assays were designed 
using the 96-well platform for large-scale drug screening 
(Figure 1B).
Selection of drugs targeting CSC phenotype
As an initial trial, we plated the iCSCL-10A cells 
in  96-well  plates  and  tested  73  organic  compounds 
using our three assays in parallel (Figure 2A). We used 
the compounds at relatively lower concentration (1 μM) 
in order to avoid redundant cytotoxicity. The selective 
toxicity against CSC-like cells was then determined using 
the WST-8 assay to monitor cell viability (Figure 2B). 
Cellular stemness was measured by monitoring expression 
of the stem cell marker ALP (Figure 2C). Interestingly, we 
found that a single compound (No. 36) drastically reduced 
the number of ALP-positive cells with limited cytotoxicity 
at 1 μM where cell viability was greater than 80%. The 
compound was identified as Withaferin A (WA) (Figure 
2B and C). We next conducted a high-throughput tumor 
sphere formation assay. We designed a platform of tumor 
sphere formation for as short as 48 hrs to maximize the 
rapidity of the assay. We also noticed that WA significantly 
suppressed  tumor  sphere  formation  highlighting  its 
function to abrogate the self-renewal ability of iCSCL-
10A cells (Figure 2D). Based on our initial finding, WA 
was selected for further characterization.
We conducted parallel experiments using varying 
concentrations  of  WA.  Our  results  revealed  that  the 
stemness of iCSCL-10A cells was abrogated at 0.25 μM 
of WA as observed using the ALP assay, while the cell 
viability  was  inhibited  at  concentrations  greater  than Oncotarget 8667 www.impactjournals.com/oncotarget
2μM of WA (Figure 3A,B). Tumor sphere formation was 
inhibited at concentrations as low as 0.125 μM (Figure 
3C, D). Collectively, these results indicate that WA could 
selectively inhibit the stemness of iCSCL-10A cells at 
relatively low concentrations compared to its impact on 
cell viability at 10-fold to 15-fold higher concentrations. 
We hereafter used 1μM WA in our further studies since the 
effect of WA was prominent at this concentration despite 
of the minimum cytotoxicity.
WA is the most abundant constituent of Withania 
somnifera, also known as Ashwagandha, which has been 
studied extensively for its biologically active constituents, 
steroidal  lactones  and  withanolides  [26].  To  further 
explore the anti-CSC function of WA, we next investigated 
the activity of three WA compound analogues, Withanone, 
Withanolide  A  and  12-Deoxywithastramonolide  (12-
DWS) (Figure 4A). The parallel experiments for ALP 
staining and the tumor sphere assays revealed that none of 
the WA analogues abrogated the stemness and self-renew 
ability of iCSCL-10A cells (Figure 4B-E), suggesting that 
the anti-CSC properties were specific to WA.
WA reduces the expression of stem cell and EMT 
markers 
We  further  examined  the  effects  of  WA  on  the 
expression of stem cell markers on iCSCL-10A as measure 
of stemness. It has been well established that the CD44+/
CD24low fraction identifies the CSC population in solid 
tumors  [13].  WA  treatment  significantly  reduced  for 
this fraction of iCSCL-10A cells (Figure 5A). Reverse 
transcription polymerase chain reaction (RT-PCR) analysis 
demonstrated that the expression of stem cell markers, 
ALDH1A1  and  Nanog,  were  prominently  reduced  in 
iCSCL-10A  cells  treated  with  WA  as  compared  with 
DMSO-treated control cells (Figure 5B). Concomitantly, 
WA reduced the expression of specific stem cell markers 
Figure 1: The induced CSC-like model and drug screening method. (A) Non-tumorigenic MCF-10A cells were subjected to 
oncogenic reprogramming via the transduction of defined reprogramming factors (4TFs) to generate iPS-like cells (iPSL-10A). To generate 
iCSCL-10A cells with CSC properties, the iPSL-10A cells were then partially differentiated via embryoid body formation. The iPSL-
10A cells acquired the ability to form hierarchically organized tumors composed of CSC-like cells and differentiated cells with multiple 
lineages. (B) Schematic of our drug screening method. To identify compounds with a low cytotoxicity and that abrogated CSC stemness, 
cell viability, cellular stemness and tumor sphere formation assays were performed in parallel.Oncotarget 8668 www.impactjournals.com/oncotarget
Figure 2: Screening of natural compounds that selectively impede the stemness of iCSCL-10A cells. (A)  A 
list  of  natural  compounds  assayed  in  the  study.  (B,  C)  iCSCL-10A  cells  (5x103  cells/well  in  100  μl)  were  plated  in  96-well 
plates.  After  24  hrs,  1  μM  of  compound  was  added  to  the  appropriate  wells.  Cell  viability  was  measured  after  48  hrs  using 
WST-8  (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium)  activity  assays  (B).  Alkaline 
Phosphatase  (ALP)  activity  was  measured  after  48  hrs  using  the  TRACP  &  ALP  Assay  Kit  and  a  microplate  reader.  Values 
represent the mean ± SEM (n = 3) (C). (D) Quantification of tumor sphere formation. iCSCL-10A cells were plated on ultra-low 
attachment  surface  96-well  plates  in  the  presence  of  1μM  of  the  compounds  and  tumor  sphere  formation  was  assessed  at  48  hrs. Oncotarget 8669 www.impactjournals.com/oncotarget
SOX2 and Nanog as measured by immunoblotting (Figure 
5C). Epithelial-mesenchymal transition (EMT) is closely 
associated with the properties of CSCs [18]. We then 
assessed whether WA treatment modulated the expression 
of  EMT  regulators.  WA  treatment  downregulated  the 
major  EMT  markers,  Twist  and  Slug  (Figure  5C). 
Therefore, WA seems to play a dual role in iCSCL-10A 
cells by suppressing the expression of both stem cell and 
EMT markers. 
WA inhibits cell migration and invasion of iCSCL-
10A
A key property of CSCs is its invasive ability. To 
examine the effect of WA on the invasion of CSCs, we 
performed a chamber invasion assay using matrigel-coated 
transwells. We found that WA treatment in iCSCL-10A 
cells resulted in a markedly reduced capacity for the cells 
to undergo invasion (Figure 5D). 
Another important feature of CSCs is their increased 
mobility. To evaluate whether WA affects CSC migration 
in this context, wound-healing assays were performed. WA 
treatment significantly inhibited the wound healing ability 
of iCSCL-10A cells (Figure 5E). Therefore, WA treatment 
profoundly  inhibits  the  tumor  invasion  and  migration 
properties of CSCs.
WA disrupts the microenvironment of CSC-like 
spheres
To  examine  the  effect  of  WA  on  CSC 
microenvironment, pre-formed tumor spheres were treated 
with either WA or DMSO followed by morphological and 
cell viability analyses (Figure 6A). It was notable that 
WA significantly reduced the viable cell numbers forming 
tumor spheres. Concomitantly, tumor spheres exhibited 
irregular morphology with notched structure around the 
rims upon WA treatment while no such inhibitory effect 
was observed in cells treated with DMSO (Figure 6B, C). 
These results suggest that WA can penetrate into tumor 
spheres and may disrupt the microenvironment that can be 
important for the maintenance of CSC stemness. 
WA inhibits the tumorigenicity of iCSCL-10A 
We  subsequently  assessed  the  in vivo  tumor-
forming  ability  of  cells  treated  with  WA.  For  these 
Figure 3: Withaferin A inhibits self-renewal and pluripotent properties of iCSCL-10A cells. (A, B) iCSCL-10A cells were 
treated with the indicated concentrations of WA and ALP activity was measured after 48 hrs. Phase contrast images of ALP staining in 
iCSCL-10A cells treated with WA (A). Nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI). Scale bar, 500 mm. Cell 
viability was measured after 48 hrs using WST-8 activity assays. Alkaline Phosphatase (ALP) activity was measured after 48 hrs using the 
TRACP & ALP Assay Kit and a microplate reader. Values represent the mean ± SEM (n = 3) (B). (C, D) iCSCL-10A cells were plated in 
the presence of the indicated concentrations of WA and tumor sphere formation was assessed after 48 hrs. Phase contrast images of tumor 
spheres (C). Values represent the mean ± SEM (n = 3) (D). Scale bar, 500 mm.Oncotarget 8670 www.impactjournals.com/oncotarget
experiments, iCSCL-10A cells were treated with varying 
concentrations of WA in vitro for 72 hrs prior to injection 
into immunosuppressed mice. We observed that iCSCL-
10A had a strong tumorigenic property forming tumor 
mass for only 10 to 12 days as shown in DMSO-treated 
control cells (Figure 6D). On the other hand, the pre-
treatment of WA had a dose-dependent anti-tumor effect 
on iCSCL-10A cells in both tumor initiation and tumor 
size (Figure 6D, E). 
Next, we assessed the optimal duration for WA pre-
treatment for inhibiting tumor formation of CSCs. iCSCL-
10A cells were treated with 1.5 μM of WA for varying 
hours  prior  to  being  injected  into  immunosuppressed 
mice. WA pre-treatment for more than 24 hrs significantly 
decreased both the tumor initiation and the tumor-forming 
ability of iCSCL-10A cells (Figure 6F, G). Taken together, 
these results indicate that the pre-treatment with WA can 
abrogate the tumorigenic properties of iCSCL-10A cells. 
Figure 4: The effect of Withaferin A analogues on the expression of phenotypic CSC properties. (A) Chemical structures 
of Withaferin A, Withanone, Withanolide A and 12-Deoxywithastramonolide (12-DWS). (B, C) iCSCL-10A cells were treated with 1 μM 
of Withaferin A, Withanone, Withanolide A, or 12-DWS for 48 hrs followed by the ALP assay. Phase contrast images of ALP staining (B). 
Values represent the mean ± SEM (n = 3) (C). Scale bar, 500 mm. (D, E) iCSCL-10A cells treated with 1 μM of Withaferin A, Withanone, 
Withanolide A and 12-DWS for 48 hrs and the tumor spheres were enumerated. Phase contrast images of tumor spheres are shown (D). 
Scale bar, 500 mm.Values represent the mean ± SEM (n = 3, E). Oncotarget 8671 www.impactjournals.com/oncotarget
WA induces the senescence of iCSCL-10A 
We next determined the mechanism regulating WA-
mediated abrogation of stemness and malignant properties 
of CSCs. Light microscopy revealed that cell morphology 
was drastically changed following WA treatment. Cells 
that were treated with WA were enlarged, flattened and 
irregular shaped, and they contained increased intracellular 
granules which were reminiscent of cellular senescence 
(Figure 7A). These cells were also positively stained with 
senescence-associated β-galactosidase (SABG) which was 
not detected in the DMSO-treated cell population (Figure 
7A). To further support this observation we tested another 
Figure 5: Withaferin A suppresses the CSC properties of iCSCL-10A cells. (A) Flow cytometric analysis of CD44 and CD24 
expression in iCSCL-10A cells treated for 48 hrs with DMSO (control) or WA (1 μM). The numbers indicate the percentage of each 
subpopulation according to the CD44/CD24 expression profile. (B) Semi-quantitative PCR for ALDH1A1 and Nanog in iCSCL-10A cells 
treated for 48 hrs with DMSO or 1μM WA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was analyzed as a control. 
(C) Immunoblotting of stem cell and EMT marker proteins in iCSCL-10A cells treated for 48 hrs with DMSO or 1μM WA. Vinculin 
was used as a loading control. (D) Cell invasion assays were performed using chemotaxis chambers in transwell tissue culture dishes as 
described in the Materials and methods. After 48 hrs of treatment with DMSO or 1μM WA, iCSCL-10A cells were seeded in transwells. 
Representative microscopic fields are shown (upper). Invasive cells were counted and transwells were scored in triplicates. The mean 
values ± SD were calculated from three independent experiments (lower). (E) Effects of WA on wound healing. Confluent monolayers of 
iCSCL-10A cells were treated for 48 hrs with DMSO or 1 μM WA and a wounded was made using a pipette tip. After 6 hrs, the cells were 
fixed, images were captured and wound closure was scored using ImageJ software. Phase contrast microscopy images of the cells are shown 
(upper). Values represent the mean ± SEM (n = 3, lower). Scale bar, 1 mm. Oncotarget 8672 www.impactjournals.com/oncotarget
senescence-associated marker γH2AX, a phosphorylated 
form of the histone variant H2AX [27]. We detected large 
phosphorylated H2AX foci in the WA treated cells but not 
in the DMSO-treated cells (Figure 7B). However, DNA 
damage response was not increased upon WA treatment as 
revealed by comet assay (Figure 7C) [28]. These results 
strongly indicate that the abrogation of CSC properties in 
iCSCL-10A cells is mediated by WA-induced senescence. 
The  expression  pattern  of  cell  cycle  regulatory 
proteins was examined in WA-treated cells. There was a 
Figure 6: Withaferin A disrupts microenvironment and tumorigenicity of iCSCL-10A cells. (A-C) Time schedule of the 
experiment (A). iCSCL-10A cells were dissociated and then cultures for 4 days to form spheres in ultra-low attachment surface plates 
followed by the treatment of WA for another 3 days. At 7 days, cell viability was monitored by CellTiter-Glo™ Luminescent Cell Viability 
Assay (C). Values represent the mean ± SEM (n = 3). Phase contrast images of tumor spheres (B). (D, E) iCSCL-10A cells were pre-treated 
with the indicated concentrations of WA for 72 hrs, and the tumor seeding ability of the cells was assessed by injecting 1x106 cells into nude 
mice. The tumor initiation ability per injection was monitored at different concentrations. Kaplan–Meier tumor-free survival curves mice 
receiving each cell types after injection at day 0. Statistically significant differences were observed between DMSO v.s. 1 mM and DMSO 
v.s. 1.5 mM, respectively (*, P<0.01) (D). Tumor size was monitored with by external caliper at indicated time points (E). Data represent 
means of 12 mice per condition. (F, G) iCSCL-10A cells were treated with 1.5 μM of WA for the indicated amount of time. WA treated cells 
(1x106 cells) were then injected subcutaneously into nude mice and the tumor initiating ability of the cells was then monitored over time. 
Tumor-free survival (F) and tumor size (G) was monitored as in (D) and (E). Statistically significant differences were observed between 0 
hr v.s. 24 hr and 0 hr v.s. 48 hr, respectively (*, P<0.01). Data represent means of 12 mice per condition.Oncotarget 8673 www.impactjournals.com/oncotarget
prominent increase in the expression of p21Cip1 following 
treatment with WA, whereas p53 protein levels remained 
largely unchanged (Figure 7D). p16Ink4a expression was 
not observed due to deletion of INK4A/ARF locus in 
parental  MCF-10A  cells  (Figure  7D)  [29].  Cyclin  B 
protein expression was markedly increased at the early 
time points but was suppressed after 24 hrs while cyclin 
D1 was increased at 48 hrs, which was further indicative 
of cellular senescence [28, 30]. It was shown that the 
activation of mitogenic pathways such as mammalian 
Figure 7: Withaferin A induces cellular senescence and increases p21Cip1 expression in iCSCL-10A cells. (A) iCSCL-
10A cells were treated with DMSO or 1μM of WA for 48 hrs and then stained for senescence-associated b-galactosidase (SABG). Phase 
contrast microscopy images of the cells are shown (upper). Scale bar, 100 mm. Bars indicate the percentage of SABG-positive cells for 
each condition and the data shown indicate mean ± SEM (n = 3, lower). One hundred cells per condition were counted and scored. (B) 
Immunofluorescent analysis of phospho-Histone H2A.X in iCSCL-10A cells treated with DMSO or 1μM of WA for 48 hrs. Nuclei were 
counterstained with DAPI. Phase contrast microscopy images of the cells are shown (upper). Scale bar, 100 mm. The number of phospho-
Histone H2A.X cells was calculated and scored for three independent experiments (lower). Data shown are the mean ± SEM. One hundred 
cells per condition were counted and scored. (C) Cells were treated as in (B) and subjected to single-cell electrophoresis under denaturing 
conditions (comet assay). As a positive control, cells treated with10 μg/ml etoposide for 1 hr. (D) Immunoblotting of cell cycle related 
proteins in iCSCL-10A cells treated with 1 μM of WA at the indicated time points. Vinculin was used as a loading control.Oncotarget 8674 www.impactjournals.com/oncotarget
target of rapamycin (mTOR) or mitogen-activated protein 
kinase  (MAPK)/mitogen-activated/extracellular  signal-
regulated  kinase  (MEK)  drives  geroconversion  from 
cell  cycle  arrest  to  senescence  [30,  31].  Indeed,  both 
phosphorylated S6 ribosomal protein (pS6) as a marker of 
mTOR and phosphorylated extracellular signal-regulated 
Figure 8: p21Cip1 suppresses CSC properties and induces cellular senescence of iCSCL-10A cells. (A) Whole cell lysates 
from iCSCL-10A cells transduced with the cyclin-dependent kinase inhibitor 1 (CDKN1) encoding p21Cip1 or empty vector (EV) control 
retrovirus were subjected to immunoblotting for the expression of the indicated proteins. β-Actin was used as a loading control. (B) CDKN1-
transduced iCSCL-10A cells were stained with senescence-associated β-galactosidase staining (SABG). Phase-contrast microscopy images 
of the cells are shown (upper). Arrows indicate positive staining shown in blue. Scale bar, 200 mm. The graph shows the percentage 
of SABG-positive cells for each condition (lower). Data shown indicate the mean ± SEM (n=3). (C) Flow cytometic analysis for the 
expression of CD44 and CD24 in iCSCL-10A cells transduced with CDKN1 or empty vector (EV). The graph shows the frequency of 
CD44+CD24low cells in each of the culture conditions. (D) CDKN1 transduction abrogates the tumor sphere-forming ability of iCSCL-10A 
cells. Phase-contrast microscopy images of tumor spheres produced by iCSCL-10A cells transduced with CDKN1 or empty vector (EV) 
(upper). Data shown indicate the number of tumor spheres (means ± SEM, n=3, lower). (E, F) iCSCL-10A cells were transfected with 
p21Cip1-siRNA for 48 hrs and then treated with 1μM WA for another 48 hr. Expression of p21Cip1 was assessed by immunoblot analysis 
(E). β-Actin was used as a loading control. Cells were stained with senescence-associated β-galactosidase staining (SABG). Phase contrast 
microscopy images of the cells are shown (upper). The graph shows the percentage of SABG-positive cells for each condition (lower). Data 
shown indicate the mean ± SEM (n=3) (F). Oncotarget 8675 www.impactjournals.com/oncotarget
kinase (pErk1/2), as a marker of MAPK activity, were 
highly expressed in WA-treated cells during the course 
of  senescence  (Figure  7D).  Moreover,  there  was  no 
prominent  cleavage  of  PARP  (Figure  7D),  strongly 
suggesting that the cells underwent senescence rather than 
apoptosis. 
Ectopic p21Cip1 expression largely recapitulates 
WA treatment in iCSCL-10A cells
In  our  iCSCL-10A  cells,  WA  induced  p21Cip1 
during  the  course  of  cellular  senescence.  In  previous 
studies, expression of p21Cip1 was tightly linked to cellular 
senescence  [28,  32].  Therefore  we  evaluated  whether 
p21Cip1  played  a  role  in  WA-induced  senescence  and 
resultant abrogation of CSC tumorigenicity. To test this 
hypothesis, iCSCL-10A cells were transduced with the 
cyclin-dependent kinase inhibitor 1 (CDKN1) encoding 
p21Cip1 using a retrovirus vector followed by selection with 
puromycin. Immunoblot analysis confirmed the stable 
expression of the ectopic p21Cip1 in CDKN1-transduced 
cells  (Figure  8A).  CDKN1-transduced  cells,  but  not 
control  vector  transduced  cells,  exhibited  a  flattened, 
enlarged, and heterogeneous cell morphology which was 
characteristic of cells in senescence (Figure 8B). These 
cells  also  expressed  SABG,  which  was  not  observed 
among the control vector transduced cells (Figure 8B). 
Concomitantly,  the  CD44+CD24low  fraction  within  the 
CSC population was significantly reduced in the CDKN1-
transduced  cells  (Figure  8C).  Furthermore,  CDKN1 
transduction significantly reduced the rate of tumor sphere 
formation (Figure 8D). 
On  the  contrary,  the  targeted  depletion  of 
endogenous  p21Cip1  by  two  different  forms  of  siRNA 
prominently  prohibited  the  WA-induced  cellular 
senescence in iCSCL-10A cells as revealed by SABG 
staining in line with the suppression of WA-induced p21Cip1 
expression (Figure 8E, F). Taken together these results 
indicate that the expression of p21Cip1 can abrogate the 
CSC properties of iCSCL-10A cells through the induction 
of cellular senescence. 
DISCUSSION
In  our  current  study,  we  developed  and  used 
an  in vitro  CSC-like  model  for  the  identification  and 
characterization of novel agents targeting CSCs based 
on  phenotypic  properties.  Several  recent  studies  have 
attempted to use cell sorting to enrich a subpopulation 
of  cancer  cell  lines  as  a  potential  CSC-like  model 
[33].  However,  a  major  limitation  of  these  studies  is 
the use of cell surface markers that may or may not be 
restricted to CSCs, and in some cases may be improved 
when combined with other properties [34]. Our current 
approach for creating a CSC-like cell population to assay 
the biological functions of CSCs sought to overcome these 
limitations by utilizing an iPSC technology for cellular 
reprogramming  and  subsequent  partial  differentiation 
of immortalized human mammary epithelial cells [24]. 
Although our technique manipulates iPS-like cells with 
further  differentiation  and  transformation,  the  cells 
express CSC markers and retain the ability to differentiate 
into multiple lineages of cancer cells following in vivo 
transplantation  into  immunosuppressed  mouse  [22]. 
Forming the self-niche, cells can be maintained in regular 
cell culture medium without the need for co-culturing 
feeder cells to maintain the stemness. Our CSC-like model 
system improves the ease of characterization of cancer 
stem cells by enabling the examination of CSC-specific 
functions,  such  as  self-renewal  and  tumor-initiating 
properties.
In  our  current  study,  we  utilized  three  different 
assays,  cell  viability,  tumor  sphere  formation  and 
differentiation assays. Using our approach, we directly 
analyzed stemness and tumorigenic properties of CSC-
like  cells  by  monitoring  their  phenotypic  features. 
WA was identified as a potential anti-CSC compound 
using our assay system, and was further validated with 
subsequent biological analyses. In fact, WA abrogated 
the maintenance of stemness and tumorigenicity via the 
induction of cellular senescence. Given the selectivity 
of our assay, future studies may be performed to identify 
additional compounds that prohibit CSC properties in 
large-scale analyses. In this regard, our approach would 
be useful not only for the identification of new targets for 
cancer therapy but also to improve the understanding of 
molecular pathways involved in the maintenance of CSCs. 
We  demonstrate  here  that  WA  can  abrogate  the 
tumorigenicity of CSC-like cells. WA is a steroidal lactone 
that  is  extracted  from  traces  in  all  parts  of  Withania 
somnifera except its leaves [35]. Withania somnifera is 
one of the most ancient herbs that is used as a medicine 
and a dietary supplement [26]. Several previous studies 
illustrated the anti-cancer activity of WA both in vitro and 
in vivo [36, 37]. In fact, WA has been shown to induce 
apoptosis of human leukemia cells via inhibition of JNK 
and AKT signaling as well as inhibition of NF-κB activity 
[38].  WA  also  inhibited  the  growth  of  breast  cancer 
cells by reducing the levels of Notch family proteins in 
MCF-7 and MDA-MB-231 cells [39]. WA has been also 
shown to induce mitotic catastrophe and growth arrest in 
prostate cancer cells [40]. These results indicate that WA 
may target distinct signaling molecules for its anti-cancer 
activity depending on the type of cancer cell. Notably, 
Kim et al. recently reported that WA treatment inhibited 
the  mammosphere  formation  in  MCF-7  and  SUM159 
human  breast  cancer  cell  lines  as  well  as  mammary 
epithelial cells derived from MMTV-neu mice [41]. In 
addition to this, we here revealed a distinct function of WA 
to target and disrupt self-renewal pathways of CSC via 
inducing p21Cip1 and suppressing Twist thereby inducing Oncotarget 8676 www.impactjournals.com/oncotarget
cellular senescence program possibly via cell cycle arrest 
and subsequent geroconversion (Figure 9). An improved 
understanding of the molecular link between WA and its 
regulation of CSC properties as revealed by in the current 
study may shed new light on the molecular signature of 
CSCs. Moreover, the identification of WA as a novel drug 
that targets CSCs may validate the feasibility of our assay 
system for anti-CSC drug discovery.
We show here that p21Cip1 plays a crucial role in 
the abrogation of the malignant properties of CSCs via 
the induction of senescence. p21Cip1 is a potent cyclin-
dependent  kinase  (CDK)  inhibitor  that  functions  as  a 
downstream effector of tumor suppressors including p53 
and FOXO1 [32, 42]. Recent reports indicated crucial 
roles of p21Cip1 not only in cell cycle regulation but also 
in the maintenance of normal and cancer stem cells. In the 
absence of p21Cip1, hematopoietic stem cell proliferation 
and their absolute number were increased under normal 
homeostatic conditions [43]. Therefore, p21Cip1 is regarded 
as a molecular switch governing the entry of stem cells 
into  the  cell  cycle,  and  in  its  absence,  increased  cell 
cycling leads to stem cell exhaustion. p21Cip1 has been 
also shown to attenuate Ras- and c-Myc-dependent breast 
tumor epithelial-mesenchymal transition and cancer stem 
cell gene expression in vivo [44]. Our current study also 
uncovered that p21Cip1 plays a crucial role for cellular 
senescence in iCSCL-10A cells there by leading to the 
abrogation of their tumor-initiating properties. Moreover, 
constitutive activation of mTOR and/or MEK signaling 
also contributes to the geroconversion of iCSCL-10A cells 
toward cellular senescence [28, 30].
Activation  of  the  senescence  program  in  cancer 
cells is an attractive approach for the treatment of cancer 
[45]. In fact, cellular senescence has been recognized as 
a critical process in mammalian cells for the suppression 
of tumorigenesis and malignant transformation [46]. It is 
now clear that cellular senescence is a crucial anticancer 
mechanism that prevents the growth of cells at risk for 
neoplastic transformation into tumor initiating cells [47]. 
This crucial event can lead to the inhibition of metastatic 
dissemination, therapeutic resistance and generation of 
tumor cells with stem/progenitor cell properties [48, 49]. 
We clearly show here that WA promotes the senescence 
of  CSC-like  cells  and  limits  their  tumorigenicity  and 
malignant  characteristics.  Indeed,  only  48  hrs  of  WA 
treatment  was  sufficient  to  induce  senescence-like 
morphological changes and SABG expression in iCSCL-
10A cells. WA treatment increased the levels of p21Cip1 
in  iCSCL-10A  cells  undergoing  senescence.  Targeted 
depletion of endogenous p21Cip1 could block the WA-
induced  senescence.  On  the  other  hand,  the  ectopic 
expression of p21Cip1 largely recapitulated the induction 
of senescence and loss of CSC properties observed in 
WA-treated  iCSCL-10A  cells.  These  results  strongly 
suggest that p21Cip1 plays a major role in inducing cellular 
senescence leading to the abrogation of the malignant 
nature in WA-treated CSCs. 
WA  suppressed  the  expression  of  EMT-related 
transcription factors including Twist. Twist plays a role 
in  overcoming  cellular  senescence  and  in  generating 
tumorigenic cancer stem cells [50, 51]. Indeed, Twist 
can abrogate oncogene-induced senescence and triggers 
epithelial-mesenchymal transition (EMT). Overexpression 
of Twist was shown to completely abrogate p16Ink4a and 
p21Cip1 induction in Ras-iuduced premature senescence 
[52], suggesting that Twist is important for overriding 
cellular senescence in cooperation with oncogenes [53]. In 
our current study, WA strongly suppressed the expression 
of Twist which was in line with its induction of p21Cip1. 
EMT  is  a  process  that  is  closely  associated  with  the 
Figure 9: Withaferin A induces cellular senescence and prevents tumor initiating ability in CSC-like cells. Schematic 
presentation depicting how Withaferin A (WA) can prevent CSC stemness and tumor progression. WA enhances p21Cip1 expression and 
suppresses the expression of an EMT-related transcription factor Twist. This event initiates cellular senescence program in CSC-like cells. 
In addition, the persistent activation of mitogenic pathways such as mTOR and/or MAPK/MEK may drive geroconversion from cell cycle 
arrest to senescence. Consequently, WA can abrogate CSC properties including tumor-initiating ability.Oncotarget 8677 www.impactjournals.com/oncotarget
acquisition of invasive properties in cancer progenitor or 
pre-cancerous cells [54]. Our current findings highlight the 
potential therapeutic benefits of WA treatment as a primary 
safe-guard  system  against  malignant  transformation, 
namely, the prevention of the EMT-mediated malignant 
conversion of pre-cancerous cells into invasive cancer 
stem-like cells via the activation of senescence program 
[55].
Herein, we developed a simple, easy, cost-effective, 
and highly reproducible assay system that is applicable 
to  large-scale  drug  screenings.  Our  optimized  drug 
screen  for  CSC  differentiation  and  stemness  provides 
excellent consistency and reproducibility for the complex 
biological  process  of  CSCs.  Furthermore,  this  drug 
screen can be applied to a larger number of compounds 
to determine more selective and effective inhibitors of 
CSCs. This  current  approach  holds  great  promise  for 
future development of novel drugs to eliminate CSC and 
hopefully provide a complete cure for tumors.
MATERIALS AND METHODS 
Cell culture
iCSCL-10A cells were generated and maintained 
as  described  previously  [22].  Cells  were  cultured 
in  Dulbecco’s  Modified  Eagle’s  medium  (DMEM) 
supplemented  with  10%  FBS  and  1%  penicillin/
streptomycin. 
Chemicals
Phytochemical compounds library used in this study 
were purchased from TOKIWA PYTOCHEMICAL Co., 
Ltd (Chiba, Japan). Chemicals were diluted in DMSO to 
10 mM without further purification. 
Alkaline Phosphatase assay
iCSCL-10A cells (5x103 cells/well) were plated in 
100 ml/well in 96-well plates. After 24 hrs, 1 mM of each 
compound was added to the appropriate wells. Alkaline 
Phosphatase (ALP) activity was measured after 48 hrs 
using the TRACP & ALP Assay Kit (TaKaRa, Shiga, 
Japan). For microscopic examination, cells were stained 
using the VECTOR Red Alkaline Phosphatase Substrate 
Kit (VECTOR Laboratories, Burlingame, CA) according 
to the manufacturer’s protocol.
Cell Proliferation and Cytotoxicity Assays
Cell proliferation and cytotoxicity were evaluated 
using  the  Cell  Counting  Kit-8  (CCK-8)  (Dojindo 
Molecular  Technologies,  Kumamoto,  Japan).  WST-8 
reagent (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium)  was  added  to 
the culture medium (1:10 dilution) and absorbance was 
measured at 450 nm.
RNA isolation and RT-PCR
Total  RNA  was  extracted  using  TRIzol  (Life 
Technologies, Grand Island, NY). cDNA synthesis was 
performed with ReverTraAce-α (Toyobo, Osaka, Japan) 
in accordance with the manufacturer’s instructions. Real-
time PCR was performed with Premix ExTaq (Takara 
Bio, Shiga, Japan) using the following primers: human 
ALDH1A1  fwd-  TAAGCATCTCCTTACAGTCAC, 
rev-TGTTAAGTACTTCAAGAGTCAC;  human 
GAPDH  fwd-  GTGGACCTGACCTGCCGTCT,  rev- 
GGAGGAGTGGGTGTCGCTGT;  human  Nanog 
fwd-CAGCCCTGATTCTTCCACCAGTCCC,  rev-
TGGAAGGTTCCCAGTCGGGTTCACC.
Tumor sphere formation assay
Cells were seeded in 96-well ultra low-attachment 
surface plates (Corning) at a density of 5x103 cells/well 
and cultured in serum-free DMEM-Ham’s F12 nutrient 
mixture (1:1, v/v) supplemented with 5 mg/mL insulin, 0.5 
mg/mL hydrocortisone, 2% B27, and epidermal growth 
factor (20 ng/ml). 
Cell invasion assay 
Cell  invasion  assays  were  performed  using  24-
well transwell inserts coated with 1 mg/ml matrigel (BD 
Biosciences, San Diego, CA). Invasive cells in the lower 
chamber were counted and scored in triplicate as described 
previously [22].
Wound healing assay 
Cells were grown as a monolayer and a wound was 
made along the central axis of the plate using a pipette 
tip. The migration of cells into the wound was observed 
after 6 hrs in six randomly selected microscopic fields 
[56]. Wound closures were quantified using the image 
processing and analysis software program Image J 1.40g.
In vivo tumor formation assay
Cells were washed twice with antibiotic-free and 
serum-free cell culture medium and resuspended in 0.1 ml 
of serum-free culture medium. The cell suspension was 
mixed with an equal volume of Matrigel (BD Bioscience, Oncotarget 8678 www.impactjournals.com/oncotarget
San Diego, CA) and then injected subcutaneously into 
6-week-old BALB/c nude mice (CLEA Japan, Tokyo, 
Japan; N = 12 per condition). All animal experiments were 
performed under the guidelines and permission of Animal 
Use Protocol of Yokohama City University. 
Statistical analysis
Kaplan-Meier’s  method  with  log-rank  test  and 
Gehan-Breslow-Wilcoxon  test  was  used  to  assess  the 
differences  among  the  samples.  GraphPad  Prism  6 
(GraphPad Software, La Jolla, CA) was used for this 
purpose. A value of P < 0.01 was considered statistically 
significant.
Comet assay
Comet  assay  was  performed  using  CometAssay 
kit (Trevigen Inc., Gaithersburg, MD) according to the 
manufacturer’s instructions.
Immunostaining
For  immunostaining,  cells  were  fixed  with  4% 
paraformaldehyde (PFA) for 15 min at 4°C, washed with 
PBS, and then permeabilized using 0.1% Triton X-100 
before blocking with 5% goat serum in 0.1% BSA. Fixed 
cells  were  incubated  with  primary  antibodies  diluted 
in 0.1% BSA for 1 hr at room temperature followed by 
secondary antibody Alexa 488 or 568-conjugated anti-IgG 
(Life Technologies) as described previously [57]. 
Antibodies
The primary antibodies used in this study were as 
follows: anti-phospho-H2A.X and anti-Sox2 (Millipore, 
Billerrica,  MA,  USA),  anti-p53  and  anti-PARP  (Cell 
Signaling Technology, Beverly, MA), anti-p21, anti-Slug 
and anti-Twist (Santa Cruz Biotechnology, Dallas, TX), 
anti-p16 and anti-Cyclin B1 (BD Biosciences, San Diego, 
CA), anti-Cyclin D1 (MBL International, Nagoya, Japan), 
anti-Nanog (ReproCELL, Yokohama, Japan), anti-b-actin 
and anti-Vinculin (SIGMA-Aldrich, St. Louis, MO). 
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